NCT03927534 is a NA clinical trial of Mindful Eating in Overweight and Obesity, sponsored by Hospital Miguel Servet.

Who is sponsoring NCT03927534?

NCT03927534 is sponsored by Hospital Miguel Servet.

What drugs are being tested in NCT03927534?

Interventions in NCT03927534: Mindful Eating.

What condition does NCT03927534 study?

NCT03927534 studies Overweight and Obesity.

Is NCT03927534 still recruiting?

NCT03927534 is currently completed. Last updated 23 February 2021.

Last reviewed 2021-02-23 · How we verify

NCT03927534

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of a Mindful-eating Program to Reduce Emotional Eating

Completed NA Last updated 23 February 2021

What this trial tests

NA trial testing Mindful Eating in Overweight and Obesity in 76 participants. Completed in 30 August 2020.

Timeline

1 May 2019

Primary endpoint
31 August 2019

30 August 2020

Quick facts

Lead sponsor	Hospital Miguel Servet
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	76
Start date	1 May 2019
Primary completion	31 August 2019
Estimated completion	30 August 2020
Sites	1 location across Spain

Drugs / interventions tested

Mindful Eating

Conditions studied

Overweight and Obesity — all drugs for Overweight and Obesity →

Sponsor

Hospital Miguel Servet

Who can join

Adults 45 to 75, any sex, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mindfulness-Based Interventions have been applied in different fields to improve physical and psychological health. However, little is known about its applicability and effectiveness in Spanish adults with overweight and obesity. The aim of the present study protocol is to evaluate the feasibility and efficacy of an adapted MBI programme to reduce emotional eating in adults with overweight and obesity in primary care (PC) settings.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

'Mindful eating' for reducing emotional eating in patients with overweight or obesity in primary care settings: A randomized controlled trial.
Morillo-Sarto H, López-Del-Hoyo Y, Pérez-Aranda A, Modrego-Alarcón M, et al · · 2023 · cited 32× · PMID 36397211 · DOI 10.1002/erv.2958
Efficacy of a mindful-eating programme to reduce emotional eating in patients suffering from overweight or obesity in primary care settings: a cluster-randomised trial protocol.
Morillo Sarto H, Barcelo-Soler A, Herrera-Mercadal P, Pantilie B, et al · · 2019 · cited 14× · PMID 31753880 · DOI 10.1136/bmjopen-2019-031327
Meditation for the primary and secondary prevention of cardiovascular disease.
Rees K, Takeda A, Court R, Kudrna L, et al · · 2024 · cited 5× · PMID 38358047 · DOI 10.1002/14651858.cd013358.pub2

Verify or expand the search:

Other trials of Mindful Eating

Trials testing the same drug.

NCT07363616 — Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight · NA · recruiting
NCT06621394 — The Effect of Mediterranean Diet and Mindfulness Eating on Depression Severity in People With Obesity and Major Depressi · NA · recruiting
NCT06230107 — The Effects of Nutritional Intervention in Participants With Eating Disorders. · NA · completed
NCT06087185 — Obesity and Mindful Eating in Patients With Anxiety · NA · completed
NCT05845411 — Mindful Eating for Eating Behavior Individuals Overweight and Obesity · NA · completed

Other recruiting trials for Overweight and Obesity

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Other Hospital Miguel Servet trials

Trials by the same sponsor.

NCT06950905 — Contemplative Practice for Well-being and Self-Deconstruction in Women · NA · recruiting
NCT06904794 — Evaluation of the Gambling Habits of Adolescents and Young Adults Post-COVID-19 and Implementation of a Digital Escape R · NA · recruiting
NCT05956405 — Retraining of the Amygdala and Insula for the Treatment of Persistent Covid · NA · completed
NCT06656065 — IMR-Heart Trasplant Study · recruiting
NCT05317754 — Effectiveness of Four Deconstructive Meditative Practices on Well-being and Self-deconstruction · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03927534 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Miguel Servet
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing